JP2016513124A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513124A5
JP2016513124A5 JP2015558976A JP2015558976A JP2016513124A5 JP 2016513124 A5 JP2016513124 A5 JP 2016513124A5 JP 2015558976 A JP2015558976 A JP 2015558976A JP 2015558976 A JP2015558976 A JP 2015558976A JP 2016513124 A5 JP2016513124 A5 JP 2016513124A5
Authority
JP
Japan
Prior art keywords
compound
salt
pharmaceutical composition
pharmaceutically acceptable
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015558976A
Other languages
English (en)
Japanese (ja)
Other versions
JP6277210B2 (ja
JP2016513124A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/017534 external-priority patent/WO2014130752A2/en
Publication of JP2016513124A publication Critical patent/JP2016513124A/ja
Publication of JP2016513124A5 publication Critical patent/JP2016513124A5/ja
Application granted granted Critical
Publication of JP6277210B2 publication Critical patent/JP6277210B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015558976A 2013-02-21 2014-02-21 二環式化合物 Expired - Fee Related JP6277210B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361767531P 2013-02-21 2013-02-21
US61/767,531 2013-02-21
PCT/US2014/017534 WO2014130752A2 (en) 2013-02-21 2014-02-21 Bicyclic compounds

Publications (3)

Publication Number Publication Date
JP2016513124A JP2016513124A (ja) 2016-05-12
JP2016513124A5 true JP2016513124A5 (cg-RX-API-DMAC7.html) 2017-03-16
JP6277210B2 JP6277210B2 (ja) 2018-02-07

Family

ID=50272738

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015558976A Expired - Fee Related JP6277210B2 (ja) 2013-02-21 2014-02-21 二環式化合物

Country Status (34)

Country Link
US (3) US9115054B2 (cg-RX-API-DMAC7.html)
EP (1) EP2958888B1 (cg-RX-API-DMAC7.html)
JP (1) JP6277210B2 (cg-RX-API-DMAC7.html)
KR (1) KR102242265B1 (cg-RX-API-DMAC7.html)
CN (1) CN105026362B (cg-RX-API-DMAC7.html)
AR (1) AR094851A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014218883B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015019919A2 (cg-RX-API-DMAC7.html)
CA (1) CA2902168C (cg-RX-API-DMAC7.html)
CL (1) CL2015002358A1 (cg-RX-API-DMAC7.html)
CY (1) CY1118641T1 (cg-RX-API-DMAC7.html)
DK (1) DK2958888T3 (cg-RX-API-DMAC7.html)
EA (1) EA025294B1 (cg-RX-API-DMAC7.html)
ES (1) ES2613262T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20170247T1 (cg-RX-API-DMAC7.html)
HU (1) HUE031626T2 (cg-RX-API-DMAC7.html)
IL (1) IL240613B (cg-RX-API-DMAC7.html)
LT (1) LT2958888T (cg-RX-API-DMAC7.html)
MA (1) MA38425B1 (cg-RX-API-DMAC7.html)
MX (1) MX2015010347A (cg-RX-API-DMAC7.html)
MY (1) MY173990A (cg-RX-API-DMAC7.html)
PE (1) PE20151746A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015501793A1 (cg-RX-API-DMAC7.html)
PL (1) PL2958888T3 (cg-RX-API-DMAC7.html)
PT (1) PT2958888T (cg-RX-API-DMAC7.html)
RS (1) RS55703B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201506408TA (cg-RX-API-DMAC7.html)
SI (1) SI2958888T1 (cg-RX-API-DMAC7.html)
SM (2) SMT201700115T1 (cg-RX-API-DMAC7.html)
TN (1) TN2015000356A1 (cg-RX-API-DMAC7.html)
TW (1) TWI613182B (cg-RX-API-DMAC7.html)
UY (1) UY35338A (cg-RX-API-DMAC7.html)
WO (1) WO2014130752A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201506965B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3022176B8 (en) 2013-07-15 2019-12-25 The Regents of the University of California Azacyclic constrained analogs of fty720
TWI689487B (zh) * 2014-08-20 2020-04-01 美商必治妥美雅史谷比公司 經取代雙環化合物
WO2017053990A1 (en) 2015-09-24 2017-03-30 The Regents Of The University Of California Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment
KR102482825B1 (ko) 2016-09-02 2022-12-29 브리스톨-마이어스 스큅 컴퍼니 치환된 트리시클릭 헤테로시클릭 화합물
US11046646B2 (en) 2017-08-09 2021-06-29 Bristol-Myers Squibb Company Alkylphenyl compounds
WO2019032631A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company Oxime ether compounds
WO2021062168A1 (en) * 2019-09-25 2021-04-01 The Regents Of The University Of California Synthetic sphingolipid inspired molecules with heteroaromatic appendages, methods of their synthesis and methods of treatment
WO2025083549A1 (en) 2023-10-16 2025-04-24 Sun Pharma Advanced Research Company Limited Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
US6069143A (en) 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
CA2472680A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
ATE441654T1 (de) 2002-01-18 2009-09-15 Merck & Co Inc Edg-rezeptoragonisten
DE60330047D1 (en) 2002-01-18 2009-12-24 Merck & Co Inc "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten"
CA2477423A1 (en) 2002-03-01 2003-09-12 Merck & Co., Inc. Aminoalkylphosphonates and related compounds as edg receptor agonists
US7199142B2 (en) 2002-06-17 2007-04-03 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists
AU2004251146A1 (en) 2003-05-19 2005-01-06 Irm, Llc Immunosuppressant compounds and compositions
CA2547198A1 (en) 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
CA2583681A1 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
JP2008530135A (ja) 2005-02-14 2008-08-07 ユニバーシティ オブ バージニア パテント ファンデーション アミノ基およびフェニル基で置換されたシクロアルカンならびに5員の複素環を含むスフィンゴシン=1−リン酸アゴニスト
AU2006245438A1 (en) 2005-02-18 2006-11-16 Bellus Health (Innodia) Inc. Analogs of 4-hydroxyisoleucine and uses thereof
WO2006094347A1 (en) 2005-03-08 2006-09-14 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
RU2404178C2 (ru) 2005-03-23 2010-11-20 Актелион Фармасьютиклз Лтд Новые производные тиофена в качестве агонистов рецептора сфингозин-1-фосфата-1
AU2006240789B2 (en) 2005-04-22 2010-03-04 Daiichi Sankyo Company, Limited Heterocyclic compound
EP1893591A1 (en) 2005-06-08 2008-03-05 Novartis AG POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
JP2009506046A (ja) 2005-08-23 2009-02-12 アイアールエム・リミテッド・ライアビリティ・カンパニー 免疫抑制剤化合物および組成物
AU2007205114B2 (en) 2006-01-06 2012-11-08 Sunovion Pharmaceuticals Inc. Cycloalkylamines as monoamine reuptake inhibitors
JP2009528274A (ja) 2006-01-27 2009-08-06 ユニバーシティ オブ バージニア パテント ファンデーション 神経因性疼痛の治療法
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
AR060050A1 (es) 2006-03-21 2008-05-21 Epix Delaware Inc Compuestos moduladores del receptor de s1p y uso de los mismos
US7989472B2 (en) 2006-03-23 2011-08-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
PT2003132E (pt) 2006-04-03 2014-05-26 Astellas Pharma Inc Derivados de oxadiazole como agonistas dos s1p1
JP2009269819A (ja) 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
CL2007002594A1 (es) 2006-09-08 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de piridin-3-il, agentes inmunomoduladores; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades asociadas con un sistema inmunologico activado. .
US8217027B2 (en) 2006-12-21 2012-07-10 Abbott Laboratories Sphingosine-1-phosphate receptor agonist and antagonist compounds
GB0625648D0 (en) 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
AR064650A1 (es) * 2006-12-21 2009-04-15 Abbott Lab Compuestos agonistas y antagonistas del receptor de esfingosina-1-fosfato
CN101610674A (zh) * 2006-12-21 2009-12-23 艾博特公司 鞘氨醇-1-磷酸酯受体激动剂和拮抗剂化合物
UA98951C2 (ru) 2007-02-02 2012-07-10 Ф. Хоффманн-Ля Рош Аг 2-аминооксазолины и лекарственное средство, которое их содержит
AU2008227979B2 (en) 2007-03-16 2014-02-06 Actelion Pharmaceuticals Ltd Amino- pyridine derivatives as S1P1 /EDG1 receptor agonists
KR20100075608A (ko) 2007-10-04 2010-07-02 메르크 세로노 에스. 에이. 옥사다이졸 유도체
ES2449749T3 (es) 2007-11-01 2014-03-21 Actelion Pharmaceuticals Ltd. Nuevos derivados de pirimidina
GB0725105D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
EP2280933B1 (en) 2008-04-01 2013-07-24 Theravance, Inc. 2 -aminotetralin derivatives as mu opioid receptor antagonists
EP2344446A4 (en) 2008-10-17 2012-04-04 Akaal Pharma Pty Ltd S1P RECEPTOR MODULATORS
WO2010069949A1 (en) 2008-12-18 2010-06-24 Merck Serono S.A. Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
JP2012515788A (ja) * 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー 自己免疫疾患および炎症性疾患の処置における、s1pアゴニストとしての置換オキサジアゾール誘導体
US8389509B2 (en) 2009-01-23 2013-03-05 Bristol-Myers Squibb Company Substituted pyrazole compounds
CN102361867A (zh) 2009-01-23 2012-02-22 百时美施贵宝公司 在治疗自身免疫疾病和炎性疾病中作为s1p激动剂的取代的噁二唑衍生物
CN102316862A (zh) 2009-02-10 2012-01-11 雅培制药有限公司 制备s1p受体激动剂或拮抗剂的方法
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
ES2759949T3 (es) 2009-10-29 2020-05-12 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos
US8835470B2 (en) 2010-04-23 2014-09-16 Bristol-Myers Squibb Company Mandelamide heterocyclic compounds
CN102260178A (zh) 2010-05-25 2011-11-30 中国医学科学院药物研究所 羟基丙二醇类衍生物、其制备方法和其药物组合物与用途
CN102260177A (zh) 2010-05-25 2011-11-30 中国医学科学院药物研究所 丙二醇类衍生物、其制备方法和其药物组合物与用途
JP5788507B2 (ja) 2010-07-20 2015-09-30 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 置換3−フェニル−1,2,4−オキサジアゾール化合物
WO2012040532A1 (en) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
ES2525298T3 (es) 2010-11-03 2014-12-19 Bristol-Myers Squibb Company Compuestos heterocíclicos como agonistas del S1P1 para el tratamiento de enfermedades autoinmunes y vasculares
EP2685971A2 (en) * 2011-03-18 2014-01-22 University Of Virginia Patent Foundation Compositions and methods for tissue engineering and cell based therapies
EP2541155B1 (en) 2011-04-26 2016-02-24 Panasonic Intellectual Property Management Co., Ltd. Heating system, and heating system control method
GB201107325D0 (en) * 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
ES2758841T3 (es) 2011-05-13 2020-05-06 Celgene Int Ii Sarl Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato
MX362346B (es) 2012-07-27 2019-01-11 Biogen Ma Inc Compuestos que son agentes moduladores de s1p y/o agentes moduladores de autotaxina.

Similar Documents

Publication Publication Date Title
JP2016513124A5 (cg-RX-API-DMAC7.html)
RU2016105581A (ru) Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться
MX381180B (es) Compuestos aminopirazina con propiedades antagonistas a2a.
EP4275756A3 (en) Bipyrazole derivatives as jak inhibitors
JP2016528301A5 (cg-RX-API-DMAC7.html)
JP2016539134A5 (cg-RX-API-DMAC7.html)
AR101177A1 (es) Inhibidores de la syk
AR088458A1 (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y fingolimod
JP2010174019A5 (cg-RX-API-DMAC7.html)
EA201101709A1 (ru) Полициклические антагонисты рецепторов лизофосфатидной кислоты
EA201390821A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты и их применение
JP2017514910A5 (cg-RX-API-DMAC7.html)
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
JP2016510326A5 (cg-RX-API-DMAC7.html)
IL292465B2 (en) Neuroactive compounds and methods of use thereof
RU2019121667A (ru) Аминопиразолы в качестве селективных ингибиторов янус-киназы
JP2013518036A5 (cg-RX-API-DMAC7.html)
JP2017511377A5 (cg-RX-API-DMAC7.html)
JP2019516739A5 (cg-RX-API-DMAC7.html)
RU2017106172A (ru) Применение антагонистов cxcr2 для предотвращения и/или лечения периферической невропатии, вызванной химиотерапией (cipn)
RU2016132762A (ru) Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
JP2014513065A5 (cg-RX-API-DMAC7.html)
BR112017017211A2 (pt) composto, composição, sal farmaceuticamente aceitável de um composto, combinação, formulação farmacêutica, métodos para matar uma micobactéria e/ou inibir a replicação de micobactérias que causam doença em um animal, para tratamento de uma infecção micobacteriana em um animal e para tratamento de uma doença resultante de uma infecção por micobactéria de um mamífero, e, uso de um composto.
BR112015019919A2 (pt) compostos bicíclicos